Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment

(1) Background: We aimed to evaluate the risk of hepatitis B virus (HBV) reactivation in lung cancer patients treated with tyrosine kinase inhibitor (TKI), particularly in those with resolved HBV infection. (2) Methods: In this retrospective hospital-based cohort study, we screened all lung cancer p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Po-Hsin, Huang, Yen-Hsiang, Hsu, Yu-Wei, Chen, Kun-Chieh, Hsu, Kuo-Hsuan, Lin, Ho, Lee, Teng-Yu, Tseng, Jeng-Sen, Chang, Gee-Chen, Yang, Tsung-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820864/
https://www.ncbi.nlm.nih.gov/pubmed/36615034
http://dx.doi.org/10.3390/jcm12010231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820864/
https://www.ncbi.nlm.nih.gov/pubmed/36615034
http://dx.doi.org/10.3390/jcm12010231

Ejemplares similares